Literature DB >> 11988838

The role of alpha(v)beta(3) in prostate cancer progression.

Carlton R Cooper1, Christopher H Chay, Kenneth J Pienta.   

Abstract

Integrin alpha(v)beta(3) is involved in varied cell biological activities, including angiogenesis, cell adhesion, and migration on several extracellular matrix components. Although alpha(v)beta(3) is not typically expressed in epithelial cells, it is expressed in macrophages, activated leukocytes, cytokine-stimulated endothelial cells, osteoclasts, and certain invasive tumors. Interestingly, the adhesion and migration of breast cancer cells on bone matrix are mediated, in part, by alpha(v)beta(3). Similar to breast cancer cells, prostate cancer cells preferentially metastasize to the bone. The biological events that mediate this metastatic pattern of prostate cancer are not well defined. This review discusses the role alpha(v)beta(3) plays in prostate cancer progression, with specific emphasis on bone metastasis and on alpha(v)beta(3) signaling in prostate cancer cells. The data suggest that alpha(v)beta(3), in part, facilitates prostate cancer metastasis to bone by mediating prostate cancer cell adhesion to and migration on osteopontin and vitronectin, which are common proteins in the bone microenvironment. These biological events require the activation of focal adhesion kinase and the subsequent activation of PI-3 kinase/Akt signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11988838      PMCID: PMC1531692          DOI: 10.1038/sj/neo/7900224

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  31 in total

1.  Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites.

Authors:  Monika Schmelz; Anne E Cress; Katherine M Scott; Friederike Bürger; Haiyan Cui; Karim Sallam; Kathy M McDaniel; Bruce L Dalkin; Raymond B Nagle
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

2.  Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway.

Authors:  D Q Zheng; A S Woodard; M Fornaro; G Tallini; L R Languino
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

3.  Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line.

Authors:  J E Lehr; K J Pienta
Journal:  J Natl Cancer Inst       Date:  1998-01-21       Impact factor: 13.506

4.  Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells.

Authors:  U M Malyankar; M Scatena; K L Suchland; T J Yun; E A Clark; C M Giachelli
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

5.  Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins.

Authors:  V Lecrone; W Li; R E Devoll; C Logothetis; M C Farach-Carson
Journal:  Cell Calcium       Date:  2000-01       Impact factor: 6.817

6.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

7.  Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines.

Authors:  C M Witkowski; I Rabinovitz; R B Nagle; K S Affinito; A E Cress
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  Activation of microvascular endothelium by eicosanoid 12(S)-hydroxyeicosatetraenoic acid leads to enhanced tumor cell adhesion via up-regulation of surface expression of alpha v beta 3 integrin: a posttranscriptional, protein kinase C- and cytoskeleton-dependent process.

Authors:  D G Tang; C A Diglio; K V Honn
Journal:  Cancer Res       Date:  1994-02-15       Impact factor: 12.701

9.  Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins.

Authors:  A G Aprikian; L Tremblay; K Han; S Chevalier
Journal:  Int J Cancer       Date:  1997-07-29       Impact factor: 7.396

10.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

View more
  90 in total

1.  Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.

Authors:  Yuan Liu; Krishna Mohan Bajjuri; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

2.  Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology.

Authors:  Claudia Fredolini; Francesco Meani; Alessandra Luchini; Weidong Zhou; Paul Russo; Mark Ross; Alexis Patanarut; Davide Tamburro; Guido Gambara; David Ornstein; Franco Odicino; Monica Ragnoli; Antonella Ravaggi; Francesco Novelli; Devis Collura; Leonardo D'Urso; Giovanni Muto; Claudio Belluco; Sergio Pecorelli; Lance Liotta; Emanuel F Petricoin
Journal:  AAPS J       Date:  2010-06-12       Impact factor: 4.009

3.  Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

Authors:  Deborah A Bradley; Stephanie Daignault; Charles J Ryan; Robert S Dipaola; Kathleen A Cooney; David C Smith; Eric Small; Paul Mathew; Mitchell E Gross; Mark N Stein; Alice Chen; Kenneth J Pienta; June Escara-Wilke; Gerald Doyle; Mahmoud Al-Hawary; Evan T Keller; Maha Hussain
Journal:  Invest New Drugs       Date:  2010-03-25       Impact factor: 3.850

Review 4.  Evolving management of colorectal cancer.

Authors:  Jochem van der Voort van Zijp; Harald J Hoekstra; Marc D Basson
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

5.  Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A''-DTPA) conjugates show increased kidney accumulation.

Authors:  Mark P Borgman; Tomika Coleman; Rohit B Kolhatkar; Sandra Geyser-Stoops; Bruce R Line; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2008-07-18       Impact factor: 9.776

6.  Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Authors:  Richard Marcotte; Kevin R Brown; Fernando Suarez; Azin Sayad; Konstantina Karamboulas; Paul M Krzyzanowski; Fabrice Sircoulomb; Mauricio Medrano; Yaroslav Fedyshyn; Judice L Y Koh; Dewald van Dyk; Bodhana Fedyshyn; Marianna Luhova; Glauber C Brito; Franco J Vizeacoumar; Frederick S Vizeacoumar; Alessandro Datti; Dahlia Kasimer; Alla Buzina; Patricia Mero; Christine Misquitta; Josee Normand; Maliha Haider; Troy Ketela; Jeffrey L Wrana; Robert Rottapel; Benjamin G Neel; Jason Moffat
Journal:  Cancer Discov       Date:  2011-12-29       Impact factor: 39.397

7.  Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

Authors:  Catherine Delbaldo; Eric Raymond; Karina Vera; Luz Hammershaimb; Karen Kaucic; Stéphanie Lozahic; Michel Marty; Sandrine Faivre
Journal:  Invest New Drugs       Date:  2007-09-18       Impact factor: 3.850

8.  Expression of ADAM15 in lung carcinomas.

Authors:  A Schütz; W Härtig; M Wobus; J Grosche; Ch Wittekind; G Aust
Journal:  Virchows Arch       Date:  2005-03-09       Impact factor: 4.064

9.  Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT).

Authors:  Sylvie Kossodo; Maureen Pickarski; Shu-An Lin; Alexa Gleason; Renee Gaspar; Chiara Buono; Guojie Ho; Agnieszka Blusztajn; Garry Cuneo; Jun Zhang; Jayme Jensen; Richard Hargreaves; Paul Coleman; George Hartman; Milind Rajopadhye; Le Thi Duong; Cyrille Sur; Wael Yared; Jeffrey Peterson; Bohumil Bednar
Journal:  Mol Imaging Biol       Date:  2009-12-04       Impact factor: 3.488

10.  Correlation of integrin beta3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma.

Authors:  Shu-Guang Li; Zai-Yuan Ye; Zhong-Sheng Zhao; Hou-Quan Tao; Yuan-Yu Wang; Chun-Yu Niu
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.